September 16, 2014 5:09 AM ET

Biotechnology

Company Overview of Mirna Therapeutics, Inc.

Company Overview

Mirna Therapeutics, Inc., a biopharmaceutical company, is engaged in the development and commercialization of microRNA (miRNA) therapeutics. The company focuses on miRNA-directed oncology therapies. It offers MRX34, a series of clinical therapeutic candidates to mimic the activity of a human miRNA. Its product candidates target cancers, such as solid and blood-borne tumors with a focus on hepatocellular carcinoma, non-small cell lung cancer, colorectal cancer, and pancreatic carcinoma. The company was founded in 2007 and is based in Austin, Texas. Mirna Therapeutics, Inc. operates as a subsidiary of Asuragen, Inc.

2150 Woodward Street

Suite 100

Austin, TX 78744

United States

Founded in 2007

Phone:

512-901-0900

Fax:

512-681-5201

Key Executives for Mirna Therapeutics, Inc.

Chief Executive Officer
Age: 56
Chief Financial Officer and Secretary
Age: 54
Senior Vice President and General Counsel
Chief Medical Officer and Vice President of Oncology
Compensation as of Fiscal Year 2014.

Mirna Therapeutics, Inc. Key Developments

Mirna Therapeutics, Inc. Presents at BIO International Convention, Jun-23-2014

Mirna Therapeutics, Inc. Presents at BIO International Convention, Jun-23-2014 . Venue: San Diego Convention Center, San Diego, California, United States.

Mirna Therapeutics, Inc. Announces Interim Phase 1 Safety Data on Lead Product Candidate MRX34 at AACR Annual Meeting

Mirna Therapeutics, Inc. announced interim safety data from a multicenter, open-label Phase 1 clinical trial of MRX34 for the treatment of patients with unresectable primary liver cancer or solid cancers with liver involvement. The data show that MRX34 has a manageable safety profile with only one incident of a dose-limiting toxicity observed to date. The findings were presented by Dr. Muhammad Shaalan Beg, assistant professor of Internal Medicine and co-leader of the gastro-intestinal oncology group at University of Texas Southwestern Harold C. Simmons Cancer Center in Dallas, Texas, during an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, CA from April 5-9, 2014. The Phase 1 MRX34 study design consists of an initial dose-escalation phase of approximately 30 patients, followed by an expansion phase of approximately 18 additional patients after the recommended Phase 2 dose has been identified. MRX34 is administered intravenously (IV) twice a week for three weeks with one week off, during 28-day cycles, until disease progression or intolerance. Tumor response is measured by RECIST or modified RECIST (primary liver cancer) and evaluated by Computed Tomography/Magnetic Resonance Imaging (CT/MRI) every eight weeks. The expansion phase will include tumor biopsies and assessment of biological effect of MRX34. Data from the first 26 patients in the dose-escalation phase are included in the interim analysis. The primary objectives of the clinical trial are to establish the maximum tolerated dose and the recommended Phase 2 dose for future clinical trials. The secondary objectives are to assess the safety, tolerability and pharmacokinetic profile of MRX34 after IV dosing as well as to assess pharmacodynamics and clinical activity of MRX34.

Mirna Therapeutics Appoints Casi DeYoung as Chief Business Officer

Mirna Therapeutics announced Casi DeYoung has joined the company as chief business officer. Ms. DeYoung will be responsible for the company's corporate development and business development efforts, including planning and execution of strategic growth initiatives and external partnerships. Ms. DeYoung served as vice president of Business Development at Reata Pharmaceuticals, Inc. since 2008.

Similar Private Companies By Industry

Company Name Region
Diagnostic Biochips, Inc. United States
Smart Biosciences, Inc. United States
Pacific Pharmaceuticals United States
Elite Research, Ltd. United States
Travanti Pharma, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Mirna Therapeutics, Inc., please visit www.mirnatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.